Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-ROCKET AF: Rivaroxaban for Stroke Prevention in Japanese Patients With Atrial Fibrillation
NCT00494871Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2007
- Primary completion
- Dec 2009
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in Atrial fibrillation (AFib), stroke, systemic embolism, sponsored by Bayer. Started Jun 2007; status: completed.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)strokesystemic embolism
Beyond the preview
Go deeper on NCT00494871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494871.